Wells Fargo & Company Trims Affimed (NASDAQ:AFMD) Target Price to $25.00

Affimed (NASDAQ:AFMDFree Report) had its price target decreased by Wells Fargo & Company from $30.00 to $25.00 in a research note released on Monday, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biopharmaceutical company’s stock.

Several other equities analysts also recently weighed in on the company. StockNews.com started coverage on Affimed in a research report on Tuesday, January 2nd. They set a sell rating for the company. HC Wainwright raised their price objective on Affimed to $10.00 and gave the stock a buy rating in a report on Monday. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and an average target price of $45.00.

View Our Latest Stock Analysis on AFMD

Affimed Stock Performance

Affimed stock opened at $6.66 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.67 and a current ratio of 3.70. The stock has a fifty day moving average of $5.48 and a two-hundred day moving average of $4.92. The company has a market capitalization of $101.43 million, a price-to-earnings ratio of -0.79 and a beta of 2.05. Affimed has a fifty-two week low of $2.23 and a fifty-two week high of $11.10.

Institutional Investors Weigh In On Affimed

Hedge funds have recently made changes to their positions in the business. Price T Rowe Associates Inc. MD boosted its holdings in Affimed by 30.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 3,202 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Affimed by 0.4% in the first quarter. Vanguard Group Inc. now owns 1,386,701 shares of the biopharmaceutical company’s stock valued at $6,060,000 after acquiring an additional 5,499 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in Affimed by 1.9% in the first quarter. Bank of New York Mellon Corp now owns 302,737 shares of the biopharmaceutical company’s stock valued at $1,323,000 after acquiring an additional 5,513 shares during the last quarter. Advisor Group Holdings Inc. boosted its holdings in Affimed by 258.3% in the first quarter. Advisor Group Holdings Inc. now owns 8,967 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 6,464 shares during the last quarter. Finally, Virtu Financial LLC boosted its holdings in Affimed by 27.9% in the second quarter. Virtu Financial LLC now owns 29,836 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 6,509 shares during the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

Affimed Company Profile

(Get Free Report)

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.

Read More

Analyst Recommendations for Affimed (NASDAQ:AFMD)

Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.